目的: 深入了解我国现阶段放射性药品的检验能力和检验需求,为我国放射性药品检验机构建设和能力提升提供参考。方法: 采用调查问卷的形式,对药品检验机构、放射性药品生产单位、制备正电子类放射性药品的医疗机构进行调查,结合各机构特点分别设计问卷,主要涉及基本情况、建设意愿、在产和在研品种情况、质控能力和委托外单位检验情况、需检验机构协助解决的问题、对新增国家放射性药品检验机构的建议等,并对调查结果进行统计分析。结果: 根据29个省、自治区、直辖市反馈的122份反馈问卷显示,广东、山东、江苏等地所属的省级药品检验机构建设意愿较强。生产单位和医疗机构在产主要品种为锝[99mTc]标记药物和氟[18F]脱氧葡糖注射液,镥[177Lu]、镓[68 Ga]等新型核素放药研发增多,注射剂仍为主要研发使用剂型。均建议新建国家放射性药品检验机构。结论: 目前,我国放药生产单位和医疗机构研发热情高涨,检验需求旺盛,但自检能力较弱,建议国家合理布局放射性药品检验机构,加强检验能力建设,同时开展重点品种和剂型的质量控制研究,促进质量标准提升,服务产业发展。
Objective: To gain an in-depth understanding of the testing capacity and testing demand of radiopharmaceuticals at the present stage in China, and to provide reference for the construction and capacity enhancement of radiopharmaceutical inspection institution in China. Methods: A questionnaire was used to investigate the pharmaceutical testing institution, radiopharmaceutical production units, and medical institutions preparing positronic radiopharmaceuticals, and the questionnaires were designed in combination with the characteristics of each institution, mainly involving the basic situation, the willingness to build, the situation of the varieties in production and research, the quality control capacity and the commissioning of external testing, the problems that need to be solved with the assistance of testing organizations, the suggestions for the new national radiopharmaceutical testing organizations, etc. The results of the survey were statistically analyzed. Results: According to the 122 feedback questionnaires returned from 29 provinces, autonomous regions and municipalities directly under the central government, the willingness to build provincial-level drug testing institution belonging to Guangdong, Shandong, Jiangsu and other regions was relatively strong. The main varieties producted by production units and medical institutions were technetium [99mTc] labeled drugs and fludeoxyglucose [18 F] injection. The reasearch and development of new nuclide radiopharmaceaticals such as lutetium [177Lu], gallium [68 Ga] were increased, and injection was still the main research and development of the use of dosage forms. It is recommended to build a new national radiopharmaceutical testing organization. Conclusion: At present, China's radiopharmaceutical production units and medical institutions have high enthusiasm for research and development, strong demand for testing, but the self-test capacity is weak, it is recommended that the state rationalize the distribution of radiopharmaceutical testing institutions, strengthen the construction of testing capacity, and at the same time to carry out the quality control of key species and dosage forms of the study, to promote the improvement of quality standards, and to serve the industrial development.
[1] Rong J, Haider A, Jeppesen T, et al.Radiochemistry for Positron Emission Tomography[J]. Nature Communications, 2023,1(14):3257.
[2] 动脉网. 核药行业白皮书[EB/OL].(2023-05-06)[2023-05-06]. https://www.vbdata.cn/1518908140.
[3] 国家药品监督管理局. 放射性药品管理办法[EB/OL].(2022-03-29)[2024-03-29]. https://www.nmpa.gov.cn/xxgk/fgwj/flxzhfg/20230328171235176.html.
[4] 贾娟娟,黄宝斌,施亚琴,等. 新的特殊药品监管政策下放射性药品检验工作探讨[J]. 中国新药杂志,2023,32(3):236-240.
[5] 中国食品药品检定研究院. 中检院关于开展我国放射性药品检验需求问卷调查的通知[EB/OL].(2023-05-23)[2024-03-29]. https://www.nifdc.org.cn//nifdc/xxgk/ggtzh/tongzhi/20230523161645602149.html.
[6] 中华人民共和国卫生部,国家食品药品监督管理局. 关于印发《医疗机构制备正电子类放射性药品管理规定》的通知(国食药监安[2006]4号)[EB/OL].(2006-01-05)[2024-03-29]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjylqx/20211027164200141.html.
[7] 孙得洋,贾娟娟,黄海伟. 2011-2022 年FDA 批准的放射性药物及其在国内的应用现状[J]. 中国药物化学杂志,2023,33(9):679-695.
[8] 邱学军,崔晓艳,邵长芳,等. α核素放射性药品质量控制方法浅析[J]. 标记免疫分析与临床,2022,29(11):1977-1980.
[9] 王雪,李倩,韦薇. 浅析抗体偶联核素类产品药学研发和评价关注点[J]. 中国新药杂志,2023,32(2):143-147.
[10] 何艳,石勇平,白玉. 放射性药物仿制药药学研究关注点[J]. 中国新药杂志,2022,31(22):2227-2230.
[11] 北京市第十五届人民代表大会常务委员会. 关于修改《北京市实验动物管理条例》的决定[EB/OL].(2021-07-30)[2024-03-29]. https://www.beijing.gov.cn/zhengce/zhengcefagui/qtwj/202204/t20220413_2675868.html.
[12] 贾娟娟,张文在,弓全胜,等. 医疗机构制备氟[ 18 F]脱氧葡糖注射液的质量检验回顾及建议[J]. 同位素,2023,36(1):77-82.
[13] 李衡,刘轶,张秋华,等. 放射性药品监管现状及思考[J]. 中南药学,2022,20(9):2214-2216.
[14] 国家药品监督管理局. 国家药监局关于改革完善放射性药品审评审批管理体系的意见(国药监药注[2023]20号)[EB/OL].(2023-04-21)[2024-03-29]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20230425160128160.html.
[15] 国家药品监督管理局. 国家药监局关于发布锝标记及正电子类放射性药品检验机构评定程序的公告(2024年第21号)[EB/OL].(2024-03-07)[2024-03-29]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20240314175242120.html.
[16] 张锦明,杜进. 中国放射性药物制备的现状及展望[J].同位素,2019,32(3):178-185.
[17] 中华医学会核医学分会. 2020年全国核医学现状普查结果简报[J]. 中华核医学与分子影像杂志,2020,40(12):747-749.
[18] Zhang JJ, Lou LJ, Lv R, et al.Recent Advances in Photochemistry for Positron Emission Tomography Imaging[J]. Chinese Chemical Letters,2023,8(35): 109342.
[19] 朱亦紫,卢帅,孙凌达,等. PET显像药物 18 F-FDG 化学合成模块工艺的荟萃分析[J]. 北京师范大学学报(自然科学版),2020,56(3):52-56.
[20] 匡岩巍,杜建冬,杜婧,等. 新《药品管理法》实施后放射性药品监管法规的变化及对策分析[J]. 中国药事,2023,37(6):659-663.
[21] 贾娟娟,孙得洋,程茗,等. 氟[18F]脱氧葡糖注射液中未知杂质三甲基硅醇的研究[J]. 同位素,2023,36(2):198-202.
[22] 国家药品监督管理局药品审评中心. 国家药监局药审中心关于发布《氟[18F]脱氧葡糖注射液仿制药药学研究技术要求(试行)》的通告(2023年第57号)[EB/OL].(2023-11-30)[2024-03-29]. https://www.cde.org.cn/main/news/viewInfoCommon/dc409001fab1f82ea1f6bdef901afe28.
[23] 国家原子能机构. 关于印发《医用同位素中长期发展规划(2021-2035年)》的通知[EB/OL].(2021-06-25)[2024-03-29]. https://www.sastind.gov.cn/n10086167/n10086216/c10405915/content.html.
